JP2008504248A5 - - Google Patents

Download PDF

Info

Publication number
JP2008504248A5
JP2008504248A5 JP2007517215A JP2007517215A JP2008504248A5 JP 2008504248 A5 JP2008504248 A5 JP 2008504248A5 JP 2007517215 A JP2007517215 A JP 2007517215A JP 2007517215 A JP2007517215 A JP 2007517215A JP 2008504248 A5 JP2008504248 A5 JP 2008504248A5
Authority
JP
Japan
Prior art keywords
angiopoietin
tie
polypeptide
modulator
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007517215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/006906 external-priority patent/WO2006002854A2/en
Publication of JP2008504248A publication Critical patent/JP2008504248A/ja
Publication of JP2008504248A5 publication Critical patent/JP2008504248A5/ja
Withdrawn legal-status Critical Current

Links

JP2007517215A 2004-06-25 2005-06-27 Ｔｉｅ受容体およびＴｉｅリガンド物質および雌受胎能を制御する方法 Withdrawn JP2008504248A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58285804P 2004-06-25 2004-06-25
PCT/EP2005/006906 WO2006002854A2 (en) 2004-06-25 2005-06-27 Tie receptor and tie ligand materials and methods for modulating female fertility

Publications (2)

Publication Number Publication Date
JP2008504248A JP2008504248A (ja) 2008-02-14
JP2008504248A5 true JP2008504248A5 (https=) 2008-07-24

Family

ID=34972915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517215A Withdrawn JP2008504248A (ja) 2004-06-25 2005-06-27 Ｔｉｅ受容体およびＴｉｅリガンド物質および雌受胎能を制御する方法

Country Status (6)

Country Link
US (1) US20070280947A1 (https=)
EP (1) EP1778264A2 (https=)
JP (1) JP2008504248A (https=)
AU (1) AU2005259537A1 (https=)
CA (1) CA2571752A1 (https=)
WO (1) WO2006002854A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
AU5154098A (en) * 1996-10-31 1998-05-22 Duke University Soluble tie2 receptor
ES2262518T5 (es) * 1999-06-07 2009-05-08 Immunex Corporation Antagonistas de tek.
MXPA02009543A (es) * 2000-03-29 2005-08-26 Abbott Gmbh & Co Kg Metodo para identificar inhibidores de tie-2.
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands

Similar Documents

Publication Publication Date Title
US11673949B2 (en) Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM
CN103124788B (zh) 双特异性融合蛋白
US10227405B2 (en) Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment
OA12890A (en) Methods of diagnosing and treating pre-eclampsia or eclampsia.
US20140322225A1 (en) Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
KR20190113995A (ko) 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
HK1224174A1 (zh) 用於治疗硬皮病的抗ccl2 和抗loxl2 组合疗法
CN105524176A (zh) 双特异性融合蛋白
KR20250004742A (ko) 자궁내막증 및 다른 양성 부인과 신생물의 치료를 위한 제제
JP2008504248A5 (https=)
EP4171611A1 (en) Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
US11117976B2 (en) Compositions and methods for regulating erythropoiesis
JP2014515743A (ja) Ｔｇｆ−アルファおよびエピレグリンに結合する抗体
BR112019023141A2 (pt) métodos de tratamento seletivo da asma usando antagonistas de il-17
TW202334241A (zh) 治療硬皮病之方法
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
WO2021179106A1 (zh) 一种gp73抑制剂在制备治疗糖尿病的药物中的应用
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a & b
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
HK40082763A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
WO2025086801A1 (zh) 一种全人源tsh受体阻断性单克隆抗体及其制备和应用
CN118344475A (zh) 一种抗aibp单克隆抗体及其应用
US20180008723A1 (en) Multimeric compounds of a kringle domain from the hepatocyte growth factor / scatter factor (hgf/sf)
NZ624875B2 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
Wei et al. Expression and function of a new angiogenic factor AA98 target molecule at the maternal-embryonic boundary of rhesus monkey